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Abstract
Background: Osteoarthritis (OA) is a highly prevalent and disabling disease. It is estimated that by 2030 the
prevalence of symptomatic OA could reach 30 % of the population above 60 years. This randomised controlled trial
will investigate the effect of low-level laser therapy (LLLT) and static stretching exercises, as monotherapy and in
combination, on pain, quality of life, function, mobility, knee range of motion (KROM) and hamstring shortening in
participants with knee OA.
Methods: This study will involve 145 people aged 50–75 years with symptomatic-radiographic knee OA. It will consist of
two types of treatments: Low-level laser therapy (LLLT) and stretching exercises. The patients will be randomly allocated
to five groups LLLTACTIVE+Stretch, LLLTPLACEBO+Stretch, Stretch, LLLT and Control (n = 29 each). Treatment frequency will
be three sessions/week for all active groups. LLLT will involve the use of a Gallium-Arsenide laser (904 nm, 40 milliwatts,
3 J/point, 27 J/knee) over 24 sessions for the monotherapy group and 9 sessions for the LLLT+Stretch groups. Stretching
will consist of seven exercises completed over 24 sessions. The control group will receive a booklet. Participants will be
treated for 2 months (Stretch, LLLT and Control groups) or 3 months (LLLT + Stretch groups). Participants and
the outcome assessor will be blind to treatment allocation throughout the study.
The primary outcome is pain measured by Visual Analogue Scale. Secondary outcomes include quality of life assessed
by Western Ontario and McMaster Universities Arthritis Index, function by Lequesne Algofunctional Index, mobility by
Timed Up and Go Test, KROM by goniometry of knee flexion and hamstring shortening by popliteal angle.
The statistical method will follow the principles of per-protocol analysis.
Discussion: Although exercise therapy is considered an effective treatment in patients with knee osteoarthritis, the
knowledge of which exercise modalities would be the most appropriate for this population is lacking. LLLT has been
used as resource to increase the effects of physical therapy. However, the specific dose and treatment frequency need to
be better defined. The findings from this randomised controlled trial will provide evidence of the efficacy or otherwise,
of LLLT and stretching exercises in the management of knee OA symptoms.
Trial registration: NCT01738737 at ClinicalTrials.gov.
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Background
Osteoarthritis (OA) is the most common form of
arthritis [1] and is a leading cause of global disability
[2, 3]. The disease occurs when the dynamic equilib-
rium between deterioration and restoration becomes
unbalanced, often in situations where the mechanical
stress applied is greater than the one that can be sup-
ported by the joint tissues. OA is typically a progres-
sive disease of the whole synovial joint characterized
by progressive loss of cartilage, remodelling of sub-
chondral bone, osteophytes and synovitis. The peri
articular tissues are also affected from the disease,
resulting in muscle atrophy and ligament dysfunction.
As a consequence of these changes, joint pain and
functional disability may ensue [4].
It is estimated that 10 % of the population above
60 years have medical problems that can be attributed to
OA [5]. It is estimated that by 2030, the prevalence of
symptomatic OA will reach 30 %; attributed to increas-
ing life expectancy and the rising number of persons
with obesity [6]. Knee OA (KOA) accounts for a signifi-
cant portion of affected people. Pereira et al. [7] esti-
mated the prevalence of radiographic KOA for all age
groups and found a value of 27.3 % for women and
21.0 % for men.
Clinical manifestations include joint pain, stiffness, de-
creased range of motion (ROM), muscle weakness, pro-
prioceptive changes [8], difficulties in activities of daily
living (ADL) such as walking, climbing / descending stairs
and housekeeping [9]. Deformities and instabilities can
also be observed. Joint pain is the dominant symptom, ac-
centuated when the joint is moved and relieved with rest.
Persistent pain even during rest or at nocturnal rest may
be a sign of advanced OA [10]. Pain and stiffness are the
two primary reasons for ADL and mobility disability, ad-
versely affecting the quality of life of patients with KOA
[11] and their seeking medical attention.
Management is typically focused on symptom control
and in the first instance conservative non-pharmacologic
management (e.g. weight loss, exercise) is advocated by
most therapeutic guidelines. Physiotherapy treatment
aims to relieve pain, improve function, quality of life,
mobility, joint function, knee stabilization, reduce the
load on the joint, promote adaptation of certain activ-
ities, prevent deformities and slow the progression of the
disease [12]. Jamtvedt et al. [13] conducted an analysis
of systematic reviews related to physical therapy for
KOA and found that only exercise and weight reduction
had high quality evidence on improvement in pain and
function. Acupuncture, transcutaneous electrical nerve
stimulation (TENS) and Low Level Laser Therapy (LLLT)
had moderate quality of evidence for the same variables.
Other interventions achieved a quality rating of low or
non-existent evidence.
Recent meta-analysis on the effect of LLLT on KOA
concluded that if administered within optimum dose
levels and under a treatment regimen of 2–4 weeks,
affords clinically relevant pain relief over placebo [14].
However, a systematic review showed conflicting results
[15]. One potential reason for this conflict pointed out
by the authors is the great variability in relation to the
wavelength, dosage, localization of application points,
frequency and duration of treatment and the absence of
calibration of the laser.
LLLT has been used successfully to control pain of
various musculoskeletal disorders [16–18]. In view of
the inflammatory nature of OA, it is believed that laser
treatment can play a beneficial effect by modulating the
inflammatory process. However, the literature indicates
inconsistent results in reducing pain in persons with
KOA; one explanation for this inconsistency is the lack
of studies that specify what dosage and frequency should
be used. In our opinion, LLLT is still underutilized and
as our study proposes to test the dosage indicated by the
World Association for Laser Therapy (WALT) [19], it is
expected that the results of this research may provide
the foundation for evidence based clinical practice.
Persons with KOA tend to avoid physical activity in
an attempt to prevent pain. It was shown that this
behaviour, over time, reduces the strength of knee ex-
tensors further impairing ability to perform activities
of daily living [20]. When subjected to immobilization
or inactivity, the peri articular connective tissue be-
comes fibrotic, resulting in capsular adherence, adap-
tive shortening of muscles and consequent limitation
of ROM [21] . Studies have reported that individuals
with KOA have increased hamstring muscle activity,
preventing the joint reaching its maximum extension
during the gait cycle, a fact that further compromises
knee ROM [22, 23]. Pain and reduced ROM in af-
fected joints are important risk factors for the occur-
rence of functional disability [24]. It is presumed that
stretching performed slowly and sustainably must be
performed to change this picture.
Therapeutic exercises have proven to be beneficial
for individuals with KOA, however it is unclear which
type, frequency and intensity are more suitable. We
propose to test muscle stretching in this study in order to
ascertain if this type of exercise is appropriate for this
population. Despite their relevance, studies testing stretch-
ing exercises are scarce.
The combination of these two treatments (LLLT and
stretching) aims to relieve pain with the initial use of the
laser to enhance the effect and implementation of
stretching exercises. Thus, the hypothesis of this study
was that LLLT combined with stretching exercises would
demonstrate greater benefits for patients with KOA than
either treatment alone.
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The primary objective of this research will be to inves-
tigate the effect of static stretching and LLLT (904 nm),
in combination or as monotherapy, in the management
of pain in persons with KOA. The secondary objective
was to evaluate the influence of each intervention on
quality of life, function, mobility, knee flexion range of
motion and hamstring length of these individuals com-
pared to a control group.
Methods
Trial design
This study will be a five-arm randomised controlled trial
with blind evaluator.
Approval and registration
The procedures and consent form were approved by
the Research Ethics Committee of Faculty of Medicine
of the University of Sao Paulo (protocol no. 455/11).
The study is being funded by Fundação de Amparo à
Pesquisa do Estado de São Paulo (FAPESP) (2012/
01827–3), Coordenação de Aperfeiçoamento de Pessoal
de Nível Superior (CAPES) (Institutional) and Conselho
Nacional de Desenvolvimento Científico e Tecnológico
(CNPq) (248967/2013-4). This study was registered at
ClinicalTrials.gov - NCT01738737.
Participants
One hundred and forty-five men and women aged 50–75
years with symptomatic radiographic knee OA will be re-
cruited from the Serviço Especializado em Reabilitação
(SER) of Taboao da Serra, Sao Paulo, Brazil. This clinic
provides multidisciplinary care, with specialties in ortho-
paedics, rheumatology, neurology, psychology, physiother-
apy, occupational therapy, speech therapy, nursing and
social care. The use of this site was authorized by the Sec-
retary of Health of Taboao da Serra and by the General
Director of the establishment.
Participants will be eligible if they have (i) radio-
graphic evidence of knee osteoarthritis between 2 and
4 in Kellgren and Lawrence classification [25]; (ii)
pain intensity ≥ 3 on a 10 cm Visual Analogue Scale
(VAS); and (iii) knee symptoms for at least 3 months.
Participants will be ineligible if they (i) have symptom-
atic hip osteoarthritis; (ii) have any disease where laser
treatment is contraindicated (cancer and uncontrolled
diabetes mellitus); (iii) use continuous anti-inflammatory
drugs; and (iv) have other concurrent injury/conditions
that will affect their ability to participate in the rehabili-
tation program and/or assessment procedures.
All participants will be informed about the study’s objec-
tives, timeline, and eligibility criteria, then asked to sign
an informed consent form if they agree to take part in the
study. Participants excluded at this stage will be referred
to the physiotherapy sector and followed with the stand-
ard of care provided by the service (10 sessions).
Study procedure
All participants will be screened by an orthopaedist or
rheumatologist to diagnose and identify the severity of
KOA. The diagnosis will be based on the radiograph
analysis and physical assessment and the severity will
follow the Kellgren & Lawrence classification. After con-
firmation of KOA patients will be referred to the local
physiotherapy sector. The eligibility criteria will be ap-
plied during the prior assessment standardized by the
clinic, and when the patient is considered eligible and is
interested in participating in the study, their contact (full
name and phone number) will be passed to the study as-
sessor in order to schedule the baseline assessment.
Participants will be instructed to bring knee radio-
graphs, prescription medications taken and the referral
for physical therapy. Participants will be asked to use
comfortable clothes and not to use analgesic or anti-
inflammatory drugs 48 h prior the evaluation date, but
to continue to perform their ADLs in the usual way. On
the baseline visit, the criteria for inclusion and exclusion
will be reapplied.
Five intervention groups will be part of the study:
 LLLTACTIVE + Stretch: 3 weeks of low intensity laser
therapy (LLLT) followed by 8 weeks of stretching
exercises.
 LLLTPLACEBO + Stretch: 3 weeks of placebo LLLT
followed by 8 weeks of stretching exercises.
 Stretch: 8 weeks of stretching exercises.
 LLLT: 8 weeks of active LLLT.
 Control: minimal intervention through educational
booklet.
This study will be conducted by a trained physiotherapist.
Assessment procedures
Participants will be assessed prior to starting treat-
ment and after each intervention. The initial part of
the evaluation will consist of a socio-demographic
questionnaire, which includes personal information,
medical history, history of past and present illness,
diseases and medications taken. Participants who con-
tinuously use NSAIDs and / or medications to control
OA (glucosamine sulphate and chondroitin) will be
instructed to discontinue the drug until the end of
the trial to avoid possible research bias. The suspen-
sion of these drugs will be with the prior knowledge
of their physicians, since the study was approved by
the General Board of the SER. For pain control dur-
ing the intervention period, only analgesics (e.g. para-
cetamol, dipyrone) and thermotherapy will be allowed
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and their use recorded, but these methods will be
interrupted 48 h prior periods of reassessment in
order to avoid possible confounders.
The following instruments and tests will be used to as-
sess the participants: (i) Western Ontario and McMaster
Universities Arthritis Index (WOMAC); (ii) Lequesne
index for knee osteoarthritis; (iii) VAS; (iv) goniometry
of knee range of motion (KROM); (v) popliteal angle;
and (vi) Timed Up and Go (TUG). This data will be
collected for the knee with greater severity of symptoms.
All scales and questionnaires have been translated and
cross-culturally adapted to the Brazilian population. A
detailed description of each of the instruments is given
below.
 Western Ontario and McMaster Universities Arthritis
Index: The questionnaire contains 24 questions of
which 5 evaluate pain, 2 joint stiffness and 17 function
[26, 27]. Each question is graded qualitatively, with
the response options: none, low, moderate, severe and
very severe. The equivalent scores are 0, 1, 2, 3 and 4,
respectively. Higher scores indicate greater impact on
quality of life. Although self-administered the
questionnaire will be verbalized and filled by the
assessor in an attempt to standardize the level of
understanding of the subject and to minimize filing
errors.
 Lequesne Index: is composed of 11 questions about
pain, discomfort and function [28, 29]. One of the
items is specific for hip OA, so this question will be
deleted. Each answer has an equivalent score. The
total score ranges from 0 to 24 and is divided into five
categories of functional impairment: no = 0, bit = 1–4,
moderate = 5–7, severe = 8–10, very severe = 11–13
and extremely severe ≥ 14. In conclusion, the higher
the score, the greater the impairment of function.
 Visual Analogue Scale: The VAS has been shown to
be a reliable and valid measure of pain, which is
used frequently in clinical and research settings [30].
It consists of a 10-cm line anchored at each end.
The left-hand anchor reads ‘no pain’ and the
right-hand anchor reads ‘worst possible pain’; the
participant marks a line to represent their pain
level. Pain during movement and rest will be
measured. A ruler will measure the distance in
centimetres from the beginning of the line to the
marked point, with higher values representing
more severe pain.
 Goniometry of knee range of motion: will be
measured with a universal goniometer (CARCI).
Active extension will be measured with the
participant in a supine position with extended legs.
For goniometry of active flexion, the participant will
be in the prone position with the contralateral lower
limb in extension. The KROM will be calculated as
follows: angle of active flexion less the angle of
active extension. The measures will follow the
methodology of Marques [31].
 Popliteal angle: will be measured with a universal
goniometer. The patient will be positioned in supine
position with a ratio of 90° of hip and knee flexion
and with the contralateral limb extended. From that
position, without losing the hip flexion, the knee will
be passively stretched to the limit (joint or tissue).
The amount remaining to full extension represents
the popliteal angel.
 Timed Up and Go: this test has been shown to be
reliable, reproducible, and responsive to change [32].
Participants will be asked to rise from a standard
armchair, walk at a safe and comfortable pace to a
mark 3 m away, then return to a sitting position in
the chair, using gait aids and chair armrests to assist
with sit to stand as needed. The outcome measured
will be the time to complete the task. The longer the
time spent, the worse their mobility.
Interventions
All monotherapy groups had durations of 8 weeks, as
this duration is usually used in knee osteoarthritis
clinical trials as an effective period of treatment [33].
Additionally, this study includes two supplementary
groups with a preparatory period of 3 weeks of laser
active/placebo before the standard 8 weeks of exercise
treatment. The World Association of Laser Therapy
suggests a 2–3-week duration for laser therapy [19].
A potential group involving simultaneous laser/placebo
and stretching exercises, within a single 8-week period,
was not considered as the number of treatments per week
and the time spent would not be feasible with clinical
practice. If the chosen preparation period is found to im-
prove the standard 8-week period of exercise then further
studies could determine the optimal combination of treat-
ment durations.
Low-level laser therapy (LLLT)
The LLLT will be performed using pulsed laser, class 3B
and wavelength of 904 nm. The equipment will be the
LASERPULSE manufactured by IBRAMED (Brazil) and
with a Gallium Arsenide (GaAs) diode laser, which has
the following technical characteristics: peak power 70
W; pulse duration 60 ns; pulse repetition rate 9500 Hz
and beam area 0,1 cm2. Detailed information present in
Table 1.
The recommendations of the World Association for
Laser Therapy (WALT) for the treatment dose in KOA
will be respected. Thus, the dose of 3 J(J)/point will be
used. Real average power and exposure time were calcu-
lated based on the study of Fukuda & Malfatti [34].
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Therefore, the power for this device is 40 milliwatts and
the time required for the dose of 3 J will be 75 s(s) per
point. The probe and the laser device will be checked
regularly (every 6 months) to ensure proper function.
Nine knee points will be irradiated with LLLT: three
on the medial joint line; two on the lateral joint line and
four points over the borders of kneecap, as shown in
Fig. 1 - Application points of LLLT. Each point will re-
ceive energy of 3 J/point for 75 s, with a total dose of
27 J/knee in each session. Thus, the time of application
will be approximately 12 min/knee. All participants and
the physiotherapist will wear safety goggles to shield
their eyes from active laser radiation. For participants in
the placebo group, the treatment procedure will be iden-
tical but without switching on the machine.
Participants will assume a sitting position and the
laser probe will be placed on the knee points sequen-
tially and perpendicularly and in full contact with the
skin. All participants will attend the LLLT sessions
three times per week over a period of 3 weeks in the
combined treatment groups and for 8 weeks when
used as monotherapy.
Muscle stretching exercises
Before running stretching exercises, patients will hold a
10-min period for warming up on a stationary bike with
light load (3/9) and comfortable speed. However, those
unable to use this machine will warm-up on a treadmill
at a speed of 2.0 km/h and no slope.
The treatment will be conducted in groups of five
to seven people at a frequency of 3×/week and lasting
approximately 45 min. The intervention will last 8 weeks,
completing 24 sessions and will consist of seven segmental
stretching exercises, repeated four times and sustained for
30 s each. The intensity will follow the recommendation
of the American College of Sports Medicine [35] position-
ing with middle discomfort. Unilateral exercises are per-
formed alternately, allowing the contralateral limb to rest
during execution. For bilateral exercises, a rest period of
30 s between the repetitions will be established. Partici-
pants will be correctly positioned and the responsible
physiotherapist will guide body awareness, breathing and
alignment throughout the therapy. After completing each
exercise, individuals will adopt a posture of rest.
The major muscles of the posterior and antero-internal
hip muscle chains will be stretched: paraspinal muscle,
gluteus, iliopsoas, hamstrings, quadriceps, hip adductors
and gastrocnemius (Fig. 2 – Stretching exercises).
Control
The control group will receive an educational booklet at
the baseline visit consisting of explanations about the
disease, postures during daily activities and information
for the management of pain. The physiotherapist will ex-
plain in detail each item and make weekly telephone
follow-up questioning about doubts regarding the educa-
tional content and the participants’ state of health. Re-
assessment will occur after 8 weeks.
Randomisation and allocation concealment
The randomisation schedule will be prepared by a re-
searcher not involved in participant recruitment, assess-
ment or treatment using a computer-generated random
numbers table. There will be a 1:1 allocation ratio of
participants to each one of the five groups. Randomisa-
tion will be conducted by random permuted blocks of
same size. Each group will have 29 numbers. The list
containing this information will remain with the physio-
therapist responsible for the treatment.
A number will be assigned to participants according to
the order of their evaluation. This digit will be later lo-
cated in the list and, thus, the corresponding group will
Table 1 Device information, irradiation and treatment parameters
Device information
Manufacturer IBRAMED
Model identifier LaserPulse
Number of emitters 1
Emitter type GaAS
Beam delivery system Hand-held probe
Irradiation parameters
Parameter [unit] Value
Center wavelength [nm] 904
Spectral bandwidth [nm] 724 – 1009
Operating mode pulsed
Frequency [Hz] 9,500
Pulse duration [ns] 60 ns ± 20 %
Peak radiant power [W] 70
Average radiant power [mW] 40
Beam profile Circular
Treatment parameters
Parameter [unit] Value Additional notes
Beam spot size at target [cm2] 0.13090
Irradiance at target [mW/cm2] 305.6
Exposure duration [sec] 11 min and 25 s Per knee
Radiant exposure [J/cm2] 22.9
Radiant energy [J] 3 Per knee
Number of points irradiated 9 points per knee
Area irradiated [cm2] 0.13090 Per point
Application technique Contact with pressure
Number and frequency
of treatment sessions
9 treatments
total - 3×/week
Total radiant energy [J] 27 Per knee
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be identified. The assessor will perform the assessment
unaware of the group to which each participant will be-
long. After the initial evaluation, the participant will be
informed by the physiotherapist responsible of the type,
time and frequency of treatment.
Statistical analysis
All data will be submitted to a descriptive inferential ana-
lysis. For adherence to normality, the Kolmogorov-Smirnov
test will be conducted. The intergroup comparison will be
performed by simple variance analysis (one-way ANOVA)
for data with normal distribution and the ANOVA
Kruskal-Wallis for non-normal distribution. For statis-
tically significant differences, post hoc tests like Holm-
Sidak (parametric) and Tukey test (nonparametric) will be
applied. Categorical variables will be compared by chi-
square test.
In view of the need to determine clinically important
differences, we will calculate the Relative Gain that cor-
responds to the gain that the patient obtained after the
end of treatment relative to how much they could im-
prove. The Average Gain will be calculated for inter-
group analysis and will be obtained by the difference
between pre and post intervention for each variable. The
data will be processed by the software SigmaStat 3.5.
The significance level for all analyses will be α = 0.05.
Sample size calculation
The primary outcome measure VAS (range: 0–10 cm)
was used to estimate the sample size. Using a minimal
clinically important change of two-point difference be-
tween the treatment groups and control group, with a
significance level of 0.05 (2-tailed) and a power of 80 %,
we estimated that 25 participants were needed in each
group. To allow for a 15 % drop-out rate, we aimed to
include 29 participants in each group.
Timeline
Ethics approval was obtained in December 2011 from
the Research Ethics Committee of Faculty of Medicine
of the University of Sao Paulo (protocol n° 455/11).
Recruitment and training of the assessor was carried
out in May 2012. Recruitment of participants com-
menced in June 2012. All participants completed the study
in December of 2014. We aim to finish the statistical ana-
lysis by the end of August of 2015 and after that start the
elaboration of scientific papers.
Discussion
This paper has presented the protocol for an ongoing
randomised controlled trial (RCT) to investigate the
effect of low-level laser therapy (LLLT) and static
stretching exercises, as monotherapy and in combin-
ation, on pain, quality of life, function, mobility, knee
range of motion and hamstring length in participants
with KOA.
The findings of the study will provide reliable infor-
mation that will guide the future use of LLLT in pa-
tients with KOA since the American Academy of
Orthopaedic Surgeons (AAOS) guideline was unable
to recommend for or against the use of physical
agents [36]. Regardless of the whether the findings of
the present study are positive, neutral or negative, the
results will be important for guiding evidence based prac-
tice. For example, if adding LLLT to muscle stretching
program provides greater pain relief and functional im-
provement than stretching exercises alone, this method
could be advised as an effective treatment option for
these patients. Conversely, if LLLT does not provide
Fig. 1 Application points of LLLT
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additional incremental or singular benefit then this
widely practiced intervention, would have evidence to
discourage that practice.
Guidelines and meta-analyses request more RCTs evalu-
ating type, intensity, and frequency of exercise, which may
contribute to the knowledge of dose–response relationship
as well as to the efficacy of stretching as an exercise mo-
dality in persons with knee OA. The European League
Against Rheumatism (EULAR) recommendations indicate
stretching exercises as an adjunctive treatment [37].
However, to our knowledge, no studies have verified
the effectiveness of stretching as monotherapy. This
Fig. 2 Muscle stretching exercises
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study will contribute with evidences of the use of this
modality in clinical practice and will provide additional
insights for the conservative treatment options.
It is important to note that the ethics committee did
not approve the inclusion of a group with placebo laser
as monotherapy, resulting in a study limitation.
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